EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The combination of alternating reduced-dose blinatumomab and hyper-CVAD as consolidation therapy in patients with newly-diagnosed adult B-cell acute lymphoblastic leukemia

Zixuan Li iD, Fang Liu, Chun Zhang, Jing He iD, WeiMing Li, Dairong Xie, Yuting Jiang, Ruofeng Jin, Tianran Gao, Mei Hong iD, Qiuling Wu iD

Therapeutic Advances in Hematology · 2026-07 · 17

DOI: 10.1177/20406207261479931 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Hematology, online erschienen am 14.08.2026. Verfasst von Zixuan Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Sciences Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Blinatumomab has gained attention for its effectiveness in improving overall survival in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and eradicating minimal residual disease (MRD).

Objectives

We conducted a retrospective study to assess whether combining reduced-dose blinatumomab with chemotherapy for consolidation could improve outcomes in newly diagnosed B-ALL.

Design

Patients with Philadelphia chromosome (Ph)-positive or Ph-negative B-ALL who achieved complete remission (CR) after induction received consolidation therapy consisting of blinatumomab (cycle 1, 3, 5, and 7) and hyper-CVAD (course B for cycles 2 and 6; course A for cycle 4 and 8). After completion of the cycle 2, the decisions to continue treatment or receive hematopoietic stem-cell transplantation were made based on multiple factors.

Methods

The final endpoint was molecular remission, overall survival (OS), relapse-free survival (RFS). Molecular remission referred to MRD-related methods, including MFC (multiparameter flow cytometry)-based MRD, next generation sequencing (NGS)-based MRD, and complete molecular remission (CMR). Meanwhile, we assessed the safety profile of this combination regimen, including adverse events such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).

Results

32 newly diagnosed B-ALL patients (14 Ph+ B-ALL and 18 Ph- B-ALL) achieving CR were analyzed. At the time of study inclusion, 12 Ph+ B-ALL and 12 Ph- B-ALL patients were MFC-MRD negative, and 5 Ph+ B-ALL patients achieved CMR. After the first blinatumomab consolidation and hyper-CVAD B cycle, seven additional patients (one Ph+ B-ALL and six Ph- B-ALL) achieved MFC-MRD negativity, and six additional Ph+ B-ALL patients achieved CMR. With a median follow-up of 16.5 months, the overall rate of MFC-MRD was 96.88% (Ph+ B-ALL 92.86% and Ph- B-ALL 100%), and CMR was 78.57%. The estimated RFS and OS rates at 30 months for whole patients were 83.5% (95% CI, 79.1%–100%) and 96.8% (95% CI, 90.8%–100%), respectively. The most common adverse events were observed during chemotherapy cycles due to myelosuppression. Eight patients developed a grade 1-2 blinatumomab-related CRS with a prevalence of 17.78%, which was completely reversible.

Conclusion

Reduced-dose blinatumomab combined with hyper-CVAD chemotherapy as consolidation therapy seems to be feasible for adult B-ALL with acceptable side effects.

Schlagwörter

Stichwörter der Autor:innen

adult B-cell acute lymphoblastic leukemiablinatumomabchemotherapyconsolidationretrospective study

Autor:innen und Institutionen

  • Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.

ORCID-Profile: Zixuan Li, Jing He, Mei Hong, Qiuling Wu

Förderung

  • National Natural Sciences Foundation of China

Zitieren

APA

Li, Z., Liu, F., Zhang, C., He, J., Li, W., Xie, D., Jiang, Y., Jin, R., Gao, T., Hong, M., & Wu, Q. (2026). The combination of alternating reduced-dose blinatumomab and hyper-CVAD as consolidation therapy in patients with newly-diagnosed adult B-cell acute lymphoblastic leukemia. Therapeutic Advances in Hematology, 17. https://doi.org/10.1177/20406207261479931

Vancouver

Li Z, Liu F, Zhang C, He J, Li W, Xie D, et al. The combination of alternating reduced-dose blinatumomab and hyper-CVAD as consolidation therapy in patients with newly-diagnosed adult B-cell acute lymphoblastic leukemia. Therapeutic Advances in Hematology. 2026;17. doi:10.1177/20406207261479931

BibTeX
@article{Li2026,
  author = {Li, Zixuan and Liu, Fang and Zhang, Chun and He, Jing and Li, WeiMing and Xie, Dairong and Jiang, Yuting and Jin, Ruofeng and Gao, Tianran and Hong, Mei and Wu, Qiuling},
  title = {The combination of alternating reduced-dose blinatumomab and hyper-CVAD as consolidation therapy in patients with newly-diagnosed adult B-cell acute lymphoblastic leukemia},
  journal = {Therapeutic Advances in Hematology},
  year = {2026},
  volume = {17},
  doi = {10.1177/20406207261479931}
}
Kostenlos starten →